Israel - English - Ministry of Health

lapidot medical import and marketing ltd - metronidazole - solution for infusion - metronidazole 500 mg / 100 ml - metronidazole - metronidazole - treatment and prophylaxis of infection which are or may be due to anerobic bacteria,especially bacteriodes species,including bacteriodes fragilis, fusobacterium,eurobacterium and clostridium species.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; citric acid; sodium chloride; dibasic sodium phosphate - metronidazole juno is indicated for:treatment of severe anaerobic infection when oral medication is not possible or is contraindicated, when immediate anti-anaerobic therapy is required. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.

Israel - English - Ministry of Health

lapidot medical import and marketing ltd - metronidazole - solution for infusion - metronidazole 500 mg / 100 ml - metronidazole - metronidazole - treatment and prophylaxis of infection which are or may be due to anerobic bacteria,especially bacteriodes species,including bacteriodes fragilis, fusobacterium,eurobacterium and clostridium species.

Malta - English - Medicines Authority

b braun melsungen ag carl-braun-strasse 1, d34212 melsungen, germany - metronidazole - solution for infusion - metronidazole 5 mg/ml - antibacterials for systemic use

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - metronidazole - solution for infusion - metronidazole 500 mg / 100 ml - metronidazole - treatment and prophylaxis of infection which are or may be due to anerobic bacteria, especially bacteriodes species, including bacteriodes fragilis, fusobacterium, eurobacterium and clostridium species.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; dibasic sodium phosphate dodecahydrate - metronidazole intravenous infusion is indicated:,(a) for treatment of anaerobic infections in patients for whom oral administration is not possible.,(b) where immediate anti-anaerobic chemotherapy is required.,(c) where prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. procedures of this type include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.,note: metronidazole is inactive against aerobic or facultative anaerobic bacteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections; sodium chloride - treatment of severe anaerobic infection when oral medication is not possible or is contraindicated, when immediate antianaerobic therapy is required. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.

United States - English - NLM (National Library of Medicine)

ailex pharmaceuticals, llc - bismuth subsalicylate (unii: 62tey51rr1) (salicylic acid - unii:o414pz4lpz) - the components of bismuth subsalicylate chewable tablets/ metronidazole tablets/tetracycline hydrochloride capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an h2 antagonist, are indicated for the eradication of h. pylori for treatment of patients with h. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). the eradication of h. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see clinical studies and dosage and administration ). to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptib

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - metronidazole - solution for infusion - 5 milligram(s)/millilitre - imidazole derivatives; metronidazole

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth - unii:u015tt5i8h), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. pylera in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to resu